Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551035 | 0.91 | HTR2A (0.39) | HTR2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL927361 | 0.75 | ACHE (0.41) | ALDH1A1KDM4EOPRK1 | |
| SCHEMBL7902827 | 0.74 | KDM4E (0.44) | ALDH1A1KDM4EOPRK1 | |
| SCHEMBL927301 | 0.74 | ACHE (0.41) | ALDH1A1KDM4EOPRK1 | |
| SCHEMBL927383 | 0.72 | OPRK1 (0.39) | ALDH1A1KDM4EMAPTOPRK1 | |
| SCHEMBL7913336 | 0.71 | ALDH1A1 (0.32) | ALDH1A1KDM4EMAPT | |
| SCHEMBL7911302 | 0.71 | ACHE (0.46) | ALDH1A1KDM4EMAPTOPRK1 | |
| SCHEMBL7911288 | 0.70 | PLA2G4B (0.42) | ALDH1A1KDM4EMAPT | |
| SCHEMBL7912964 | 0.70 | ACHE (0.44) | ALDH1A1KDM4EOPRK1 | |
| SCHEMBL5017678 | 0.69 | HTR2A (0.50) | HTR2AALDH1A1CYP1A2MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849774-B1 | CYCLOHEPTA(b)PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TOA EIYO LTD (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7875625-B2 | 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; | TOA EIYO LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | TOA EIYO LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012114-A1 | Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same | SLC10A6, SLC26A3, SLC9A3 | HTR2A 1026/4885ALDH1A1 438/4885ADORA3 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.